ATLANTA, Nov. 14, 2016 /PRNewswire/ -- Intent Solutions™, creator of the breakthrough medical device technology TAD™, announced today that is has successfully completed a seed round of funding of $1.5 million.
TAD, for "Take As Directed," is a smart, mobile, medication dispenser that helps patients obtain better health outcomes by helping the right patient take the right dose at the right time. TAD, which can be programed to a specific regimen and schedule, incorporates biometric access and is fully tamper resistant. The medication dispenser also records adherence data, which is sent to a cloud database for analysis, reducing errors and simplifying data reconciliation for clinical trials. "We have been quietly raising capital for several months while refining our technology and service offerings," said Sam Zamarripa, president of Intent Solutions. "In that time, we've developed strategic relationships with prospective customers, both in the US and Europe, that will give us early adopters for our platform in the first quarter of 2017." "Our field needs TAD yesterday," said Benjamin Levenson, Founder and Owner of globally recognized Origins Behavioral HealthCare, one of America's largest private and most innovative and authoritative multi-site systems of addiction and psychiatric care. Origins delivered the first fully self-contained, multi-staged research and outcome-based, continuums of care for America's sickest addicted patients. "TAD is ground-breaking because it helps verify compliance with the patient medication, and, with other data, will extrapolate to help form the basis upon which we treat the world," added Levenson, who also serves as chairman of the Levenson Foundation and board member of FacingAddiction.Org. "Everyone has a story to tell about poor medication adherence and many times these stories are tragic. The TAD dispenser will give practitioners a better way to both promote adherence for better outcomes, while also reducing misuse and abuse of certain medications."